Integrated multi-omics analysis identifies prognostic risk genes and constructs a predictive signature in diffuse...

Area of Science:

• Oncology
• Genetics
• Immunology

Background:

• Diffuse large B-cell lymphoma (DLBCL) has a complex cause and is difficult to diagnose.
• Identifying pathogenic genes is crucial for understanding DLBCL.
• Novel biomarkers are needed for improved diagnosis and treatment.

Purpose of the Study:

• To investigate potential pathogenic genes in DLBCL.
• To identify DLBCL risk genes (DRGs) and their biological functions.
• To explore the role of DRGs in the DLBCL immune microenvironment and predict drug sensitivity.

Main Methods:

• Expression quantitative trait loci-Mendelian randomization (eQTL-MR) was used to identify DLBCL risk genes (DRGs).
• Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses explored biological functions.
• Single-cell RNA sequencing (scRNA-seq) and immune infiltration analyses examined the tumor microenvironment and gene localization.

Main Results:

• Fifteen genes were identified as associated with DLBCL pathogenesis and prognosis, forming a risk gene model with an AUC of 0.787.
• GO and KEGG analyses revealed significant pathways, including NF-κB signaling.
• DRGs were linked to the DLBCL immune microenvironment, highlighting the role of immune infiltration in disease progression.

Conclusions:

• The study identified 15 risk genes as potential pathogenic and therapeutic biomarkers for DLBCL.
• These findings provide new targets for understanding DLBCL pathogenesis, diagnosis, and treatment.
• The identified genes may serve as novel biomarkers for DLBCL management.